

Contents

Contributing authors	xxvii
Preface	xxix
Acknowledgments	xxxi

1 The cell and cell division 1

Margaret J. Barch and Helen J. Lawce

1.1 The cell	1
1.1.1 Cell membrane	1
1.1.2 Cytoplasm	3
1.1.3 Nucleus	5
1.1.4 Chromosomes and their proteins	10
1.1.5 X inactivation	12
1.1.6 Satellite DNA	13
1.2 The cell cycle	14
1.2.1 Interphase	14
1.2.2 Cell division	14
1.2.3 Mitosis	15
1.2.4 Meiosis	16
1.3 Recombinant DNA techniques	19
1.3.1 Bacterial-plasmid cloning	19
1.3.2 Electrophoresis	19
1.3.3 Southern blotting	19
1.3.4 Synthetic oligonucleotides	21
1.3.5 Polymerase chain reaction	21
1.4 The human genome	21
1.4.1 Genomic DNA variations	21
References	22

2 Cytogenetics: an overview 25

Helen J. Lawce and Michael G. Brown

2.1 Introduction	25
2.2 History of human cytogenetics	25
2.3 Cytogenetics methods	29
2.3.1 Work flow	29
2.3.2 Culture methods	33
2.3.3 Harvesting	35
2.3.4 Removal of attached cells and centrifugation steps	35
2.3.5 Mitotic arrest: Colcemid*	37
2.3.6 Hypotonic treatment	37
2.3.7 Fixation	40
2.3.8 In situ harvesting	41
2.3.9 Chromosome anticontraction methods	43
2.3.10 Mechanism of action of synchrony chemicals	46
2.3.11 Additives to prevent chromosome contraction	48
2.3.12 Combination of synchrony and additives for longer chromosomes	49
2.3.13 Automatic harvesting devices and slide-making chambers/drying chambers	49

2.4 Slide-making	49
2.4.1 History of slide-making	49
2.4.2 Theory of slide-making	50
2.4.3 Slide-making variables	53
2.4.4 Wet versus dry slides	53
2.4.5 Angle of the slide	55
2.4.6 Ambient humidity and temperature	55
2.4.7 Fixative ratio	56
2.4.8 Quality and freshness of fixative	56
2.4.9 Height from which cells are dropped	56
2.4.10 Wicking effects	56
2.4.11 Air flow	57
2.4.12 Dilution factor	57
2.4.13 Slide cleaning and labeling	57
2.4.14 Slide type	57
2.4.15 Cell and culture type	57
2.4.16 Culturing and harvesting techniques	57
2.4.17 In situ cell drying	58
2.4.18 Slide-making for FISH studies	58
2.4.19 Slide aging	58
2.5 Chromosome staining	58
2.6 Chromosome microscopy/analysis	59
2.6.1 Chromosome abnormalities	60
2.6.2 Mosaicism	62
2.6.3 Chromosome breakage	65
2.6.4 Karyotyping a cell	66
2.6.5 Banded karyograms	67
2.6.6 Haploid band number and band levels	67
2.6.7 The complete cytogenetic study	68
2.6.8 Karyograms, karyotypes, and the final report	68
2.6.9 Sources of error in analysis and reporting	69
2.7 Laboratory procedure manual	69
References	70
Contributed protocols	75
Protocol 2.1 Slide-making	75
Protocol 2.2 Slide-making	76
Protocol 2.3 Making wet slides for chromosome analysis	78
Protocol 2.4 Slide-making	82
Protocol 2.5 Slide preparation	82
Protocol 2.6 Slide preparation procedure	84
3 Peripheral blood cytogenetic methods	87
<i>Helen J. Lawce and Michael G. Brown</i>	
3.1 Using peripheral blood for cytogenetic analysis	87
3.2 Special uses of peripheral blood cultures	88
3.2.1 Chromosome instability syndromes	88
3.2.2 Fragile sites	89
3.3 Peripheral blood constituents	89
3.4 Specimen handling	91
3.4.1 Stimulants	91
3.4.2 Anticoagulants	92
3.4.3 Culturing	92
3.5 Cell culture equipment and supplies	93
3.5.1 Materials for cell culture	93
3.5.2 Solutions for tissue culture	93

3.6 Harvesting peripheral blood cultures	95
3.7 Chromosome analysis of peripheral blood	95
3.8 Storage of fixed specimens	95
Acknowledgments	95
References	95
Contributed protocols	98
Protocol 3.1 Blood culture and harvest procedure	98
Protocol 3.2 High-resolution peripheral blood method	100
Protocol 3.3 Constitutional cytogenetic studies on peripheral blood	108
Protocol 3.4 Blood culture and harvest procedure for microarray confirmation studies	115
4 General cell culture principles and fibroblast culture	119
<i>Debra F. Saxe, Kristin M. May and Jean H. Priest</i>	
4.1 Definitions of a culture	119
4.1.1 Time in culture	119
4.1.2 Growth characteristics	120
4.1.3 Morphology	120
4.1.4 Tissue source	121
4.2 Basic considerations in cell culture	121
4.2.1 Culture containers	122
4.2.2 Sterilization and washing principles of cell culture	123
4.2.3 Water for cell culture	124
4.2.4 Temperature, pH, CO ₂ , and humidity control	124
4.2.5 Media	125
4.2.6 Balanced salt solution	126
4.2.7 Dispersion of monolayer cells for subculture	127
4.2.8 Antimicrobial agents and monitoring for contamination	127
4.3 Fibroblast culture	128
4.3.1 Tissue sampling and transport	128
4.3.2 Tissue sampling to exclude mosaicism	128
4.3.3 Specimen setup	128
4.3.4 Routine handling and maintenance of monolayer cultures	129
4.3.5 Preparation of cultured cells for analysis	130
4.3.6 Tracking culture age	131
4.3.7 Freezing and storage of cell lines	131
4.3.8 Transport and shipping cultured cells	132
4.4 Lymphoblastoid cell lines	132
Glossary	132
Reference	133
Additional readings	133
Contributed protocols section	134
Protocol 4.1 Solid tissue collection for establishing cultures	134
Protocol 4.2 Solid tissue transport and sendout media	135
Protocol 4.3 Tissue culture reagents	138
Protocol 4.4 Phosphate buffer solution deficient in Ca ²⁺ and Mg ²⁺	141
Protocol 4.5 Solid tissue and fibroblast culture setup	141
Protocol 4.6 Solid tissue setup and processing	142
Protocol 4.7 Flask and coverslip setup for POC/fibroblast cultures	145
Protocol 4.8 Coverslip setup for solid tissue biopsy specimens	147
Protocol 4.9 Solid tissue (fibroblast) culturing and harvesting	150
Protocol 4.10 Fibroblast culture maintenance: media feeding and changing	154
Protocol 4.11 Routine subculture of fibroblast cultures	155
Protocol 4.12 Manual harvest for flasks	157
Protocol 4.13 Treated media for contamination	158
Protocol 4.14 Fungizone-mycostatin solution for treatment of fungus/yeast contaminated cultures	158

Protocol 4.15	Mycoplasma testing	159
Protocol 4.16	Plating efficiency of serum	160
Protocol 4.17	Routine replication plating for human diploid cells	160
Protocol 4.18	Cell counting chamber method	161
Protocol 4.19	Cell viability by dye exclusion	161
Protocol 4.20	Mitotic index	161
Protocol 4.21	Growth rate-estimation of mean population doubling time during logarithmic growth	162
Protocol 4.22	Maintenance of fibroblast cultures as non-mitotic population	163
Protocol 4.23	Synchronization at S-phase with BrdU	163
Protocol 4.24	Making direct FISH preparations from abortus tissue	164
Protocol 4.25	Cryopreservation	165
Protocol 4.26	Cryopreservation with Nalgene cryogenic container	166
Protocol 4.27	Lymphoblastoid lines	167
Protocol 4.28	Freezing tissue cultures (cryopreservation)	171

5 Prenatal chromosome diagnosis 173

Kristin M. May, Debra F. Saxe and Jean H. Priest

5.1	Introduction	173
5.2	Amniotic fluid	173
5.2.1	Amniocentesis	173
5.2.2	Amniotic fluid characteristics	173
5.2.3	Cells in amniotic fluid	174
5.2.4	Specimen size	175
5.2.5	Collection container	175
5.2.6	Specimen transport	175
5.3	Culture of amniotic fluid	175
5.3.1	Open versus closed system for culture	175
5.3.2	In situ versus flask growth methods	176
5.3.3	Media and additives	176
5.3.4	Number of cultures per specimen	176
5.3.5	Number of days to first culture check	177
5.3.6	Medium addition or changes	177
5.3.7	Treatment of precipitation in cultures	177
5.3.8	Treatment of microbial contamination	177
5.3.9	Treatment of bloody specimens	177
5.3.10	Treatment of poor growth	178
5.3.11	Notifying the physician about poor growth or no growth	178
5.4	Analysis of amniotic fluid	178
5.4.1	Determining harvest times	178
5.4.2	Steps involved in harvest and slide-making	178
5.4.3	Number of slides per patient	179
5.4.4	Stains performed	179
5.4.5	Analysis of amniotic fluid	179
5.4.6	Average time to report cases	179
5.4.7	Maternal cell contamination	180
5.4.8	Mosaicism	180
5.5	Chorionic villus sampling	180
5.5.1	Amniocentesis versus chorionic villus sampling	180
5.5.2	Chorionic villus sampling procedures	181
5.5.3	Structure and cell types	181
5.5.4	Specimen transport	182
5.5.5	Specimen cleaning	182
5.5.6	Direct harvest	184
5.5.7	Villus culture	184

5.6 Analysis of chorionic villi	184
5.6.1 Routine chromosome analysis	184
5.6.2 Confined placental mosaicism and uniparental disomy	185
5.6.3 Maternal cell contamination	186
5.6.4 Fetal blood sampling	186
References	186
Contributed protocols section	188
Protocol 5.1 Amniotic fluid culture setup and routine maintenance	188
Protocol 5.2 Coverslip (in situ) harvest procedure for chromosome preparations from amniotic fluid, CVS, or tissues (manual method)	191
Protocol 5.3 Harvest of flask amniocyte cultures	193
Protocol 5.4 Amniotic fluid culturing, subculturing, and harvesting (flask method)	195
Protocol 5.5 Criteria for interpreting mosaic amniotic fluid cultures	198
Protocol 5.6 Chorionic villi sampling – setup, direct harvest, and culture	199
Protocol 5.7 Chorionic villus sampling	204
Protocol 5.8 G-Banding with Leishman's stain (GTL)	208
Protocol 5.9 Cystic hygroma fluid protocol	209
6 Chromosome stains	213
<i>Helen J. Lawce</i>	
6.1 Introduction	213
6.1.1 Definitions of banding patterns and reference tables	215
6.1.2 Slide mounting	215
6.1.3 Mounting media	216
6.1.4 Slide aging for chromosome staining methods	218
6.1.5 Conventional (solid) staining methods	219
6.2 Chromosome banding methods	220
6.2.1 Quinacrine banding (QFQ)	220
6.2.2 Giemsa banding (GTG, GTW, GAG, GTL)	222
6.2.3 C-banding (CBG)	230
6.2.4 G-11 staining	233
6.2.5 Centromere/kinetochore staining	235
6.2.6 Reverse banding (R-bands)	238
6.2.7 DAPI/distamycin A staining (DA-DAPI)	241
6.2.8 Silver staining (AgNOR) for nucleolus organizing regions	243
6.3 5-bromo-2'-deoxyuridine methodologies	246
6.3.1 Historical and theoretical perspectives	249
6.3.2 Replication banding	250
6.3.3 Sister chromatid exchanges	251
6.3.4 Technical considerations for replication banding and SCEs	251
6.4 T-banding/CT-banding	252
6.4.1 Historical and theoretical perspectives	252
6.4.2 Technical considerations	252
6.5 Antibody banding and restriction endonuclease banding	252
6.6 Destaining slides	252
6.7 FISH DAPI bands	252
6.8 Sequential staining	253
Acknowledgments	253
References	253
Contributed protocols section	266
Protocol 6.1 Conventional Giemsa staining (unbanded)	266
Protocol 6.2 Leishman's stain	266
Protocol 6.3 Quinacrine mustard chromosome staining (Q-bands)	266
Protocol 6.4 C-banding	268

Protocol 6.5	C-banding	270
Protocol 6.6	C-banding	271
Protocol 6.7	C-banding of blood slides	272
Protocol 6.8	Giemsa-11 staining technique	274
Protocol 6.9	Distamycin A/DAPI staining	275
Protocol 6.10	Chromomycin/methyl green and chromomycin/distamycin fluorescent R-banding method	277
Protocol 6.11	Bone marrow and cancer blood G-banding	278
Protocol 6.12	Trypsin G-banding	280
Protocol 6.13	Giemsa-trypsin banding with Wright stain (GTW) for suspension culture slides and in situ culture coverslips	281
Protocol 6.14	G-banding blood lymphocyte slides	284
Protocol 6.15	Cd staining	285
Protocol 6.16	CREST/CENP antibody staining	286
Protocol 6.17	AgNOR (silver staining)	287
Protocol 6.18	Sister chromatid exchange blood culture and staining	289
Protocol 6.19	Sister chromatid exchange fibroblast culture and staining	291
Protocol 6.20	T-banding by thermal denaturation	294
Protocol 6.21	CT-banding	295
Protocol 6.22	Lymphocyte culture and staining procedures for late replication analysis	295
Protocol 6.23	Destaining and sequential staining of slides	298
Protocol 6.24	Restaining permanently mounted slides	299
7	Human chromosomes: identification and variations	301
	<i>Helen J. Lawce and Luke Boyd</i>	
7.1	Understanding the basics	301
7.1.1	Chromosome heteromorphisms	301
7.2	Description of human chromosome shapes	302
7.2.1	Chromosome shapes	302
7.2.2	Karyogram arrangement	302
7.2.3	A group	302
7.2.4	B group	302
7.2.5	C group	303
7.2.6	D group	303
7.2.7	E group	303
7.2.8	F group	303
7.2.9	G Group	303
7.2.10	Sex chromosomes	303
7.3	Determination of G-banded chromosome resolution	355
7.3.1	Vancouver method	355
7.3.2	Johnson and Stallard method	355
7.3.3	Welborn method	355
7.3.4	Band determination quality control	355
	Acknowledgments	356
	Glossary	356
	References	357
8	ISCN: the universal language of cytogenetics	359
	<i>Marilyn S. Arsham and Lisa G. Shaffer</i>	
8.1	Introduction	359
8.2	Language	359
8.2.1	Centromere	360
8.2.2	Homologue	361
8.2.3	Idiogram	362
8.2.4	Karyogram	362

8.3 Karyotype	364
8.3.1 Chromosome count	365
8.3.2 Event symbols	367
8.3.3 Structural breakpoint	367
8.3.4 Spaces in a karyotype	372
8.3.5 Short form karyotype	372
8.3.6 Detailed karyotype	374
8.3.7 Karyotype order priority	374
8.3.8 Repeated description	376
8.3.9 Amending a cytogenetic karyotype	377
8.4 Numerical events	378
8.4.1 Polyploidy and endoreduplication	378
8.4.2 Near ploidy	379
8.4.3 Autosome aneuploidy	379
8.4.4 Sex chromosome aneuploidy	379
8.4.5 Pseudodiploid	380
8.5 Structural events	380
8.5.1 Deletion (del)	380
8.5.2 Dicentric (dic)	381
8.5.3 Duplication (dup)	383
8.5.4 Insertion (ins)	385
8.5.5 Inversion (inv)	385
8.5.6 Isochromosome (i)	386
8.5.7 Isodicentric (idic)	387
8.5.8 Constitutional origin (mat, pat, dn, inh, and c)	388
8.5.9 Recombinant (rec)	389
8.5.10 Ring of known centric origin (r)	390
8.5.11 Telomeric association (tas)	391
8.5.12 Translocation (t)	391
8.5.13 Uniparental disomy (upd) and loss of heterozygosity (LOH)	394
8.6 Derivative chromosomes (der)	394
8.6.1 One centric derivative	394
8.6.2 Homologue derivative	394
8.6.3 Isoderivative	395
8.6.4 Multiple events derivative	395
8.6.5 Neocentromere derivative	396
8.6.6 Ring derivative involving more than one chromosome	396
8.6.7 Whole arm derivative	396
8.7 Symbols of uncertainty	397
8.7.1 Uncertainty (?)	397
8.7.2 Additional material (add)	399
8.7.3 Homogeneously staining region (hsr)	399
8.7.4 Or	399
8.7.5 Approximation (~) range	399
8.7.6 Rings of unknown origin (r)	400
8.7.7 Marker (mar)	401
8.7.8 Double minute (dmin)	402
8.7.9 Incomplete (inc)	402
8.7.10 Composite karyotype [cp20]	402
8.8 Random versus reportable	403
8.8.1 Guidelines for reporting an abnormality	403
8.8.2 Heteromorphic variations	403
8.8.3 Common fragile sites	404
8.8.4 Rare fragile sites	404

8.9	Multiple cell lines and clones	404
8.9.1	Constitutional mosaicism	405
8.9.2	Neoplastic clonal evolvement	405
8.9.3	Mainline	405
8.9.4	Stemline (sl), sideline (sdl) and idem	406
8.9.5	Neoplastic polyploidy	407
8.9.6	Multiple stemlines	408
8.9.7	Jumping translocations	408
8.10	Fluorescence in situ hybridization	408
8.10.1	Probe validation and normal cut-off values	408
8.10.2	Signal patterns	409
8.10.3	Probe name	410
8.10.4	Metaphase FISH karyotype	410
8.10.5	Metaphase fusion FISH strategy	412
8.10.6	Chromosome paints	413
8.10.7	Interphase FISH karyotype	413
8.10.8	Interphase fusion karyotype	414
8.10.9	Break-apart probe strategy	415
8.10.10	Building a string of interphase FISH results	416
8.10.11	Paraffin-embedded malignant tissue	418
8.10.12	Bone marrow transplant chimerism	420
8.11	Microarray (arr) and region-specific assay (rsa)	420
8.12	Conclusion	422
	Acknowledgments	422
	Addendum for <i>ISCN 2016</i> updates	426
	References	426
9	Constitutional chromosome abnormalities	429
	<i>Kathleen Kaiser-Rogers</i>	
9.1	Numerical abnormalities	429
9.1.1	Clinical consequences of numerical aneuploidy	430
9.1.2	Mechanisms of aneuploidy	430
9.1.3	Mosaicism	438
9.1.4	Trisomy	439
9.1.5	Monosomy	441
9.1.6	Euploidy	441
9.1.7	Triploidy	442
9.1.8	Mosaic triploidy	443
9.1.9	Tetraploidy	443
9.2	Structural rearrangements	444
9.2.1	Mechanism for structural rearrangements	446
9.2.2	Deletions	449
9.2.3	Duplications	450
9.2.4	Inversions	451
9.2.5	Neocentromeric or analphoid chromosomes	455
9.2.6	Dicentric chromosomes	455
9.2.7	Isochromosomes	456
9.2.8	Rings	457
9.2.9	Marker chromosomes	459
9.2.10	Reciprocal translocations	460
9.2.11	Robertsonian translocations	462
9.2.12	Insertions	464
9.2.13	Complex chromosome rearrangements	466
	References	472

10 Genomic imprinting	481
<i>R. Ellen Magenis</i>	
10.1 Introduction	481
10.2 Human genomic disease and imprinting	488
10.2.1 Chromosomal syndromes	488
10.2.2 Whole chromosome uniparental disomies	490
10.2.3 Partial (segmental) uniparental disomies	492
10.3 Germ cell tumors – UPD and imprinting	493
10.3.1 Common chromosome abnormalities	493
10.3.2 Imprinting status	493
Glossary	494
References	496
11 Cytogenetic analysis of hematologic malignant diseases	499
<i>Nyla A. Heerema</i>	
11.1 Introduction	499
11.2 Myeloid leukemias	508
11.2.1 Acute myeloid leukemia (AML)	508
11.2.2 Common recurring cytogenetic abnormalities in AML	510
11.2.3 Other abnormalities recognized by the WHO	514
11.2.4 Therapy-related MDS and AML (t-MDS and t-AML)	514
11.3 Myelodysplastic syndromes	514
11.4 Myeloproliferative neoplasms	515
11.4.1 Chronic myelogenous leukemia	515
11.4.2 Chronic myelomonocytic leukemia	515
11.4.3 Polycythemia vera	516
11.4.4 Essential thrombocythemia	516
11.4.5 Primary myelofibrosis	516
11.4.6 Chronic neutrophilic leukemia	516
11.4.7 Chronic eosinophilic leukemia	516
11.4.8 Other myeloid and lymphoid disorders	516
11.5 B- and T-cell lymphoid neoplasms	517
11.5.1 Acute lymphoblastic leukemia	517
11.5.2 Chronic lymphocytic neoplasias	521
11.6 Lymphomas	522
11.6.1 B-cell lymphomas	522
11.6.2 T-cell lymphomas	525
11.7 Laboratory practices	525
11.7.1 Common cytogenetic aberrations	525
11.7.2 Cytogenetic methodology	525
Acknowledgments	533
Glossary of hematopoietic malignancies	533
References	535
Contributed protocols section	553
Protocol 11.1 Cancer cytogenetics procedure	553
Protocol 11.2 Bone marrow/leukemic peripheral blood setup and harvest procedure	558
Protocol 11.3 Bone marrow and leukemic blood culture and harvest procedure using DSP30 CPG oligonucleotide/interleukin-2 for B-cell mitogenic stimulation	560
Protocol 11.4 Culture of CpG-stimulated peripheral blood and bone marrow in chronic lymphocytic leukemia	562
Protocol 11.5 Plasma cell separation and harvest procedure for FISH analysis	567
Protocol 11.6 Plasma cell separation and harvest procedure for FISH	569

Protocol 11.7 Bone marrow GTG-banding	571
Protocol 11.8 GTW banding procedure (G-bands by trypsin using Wright stain)	573

12 Cytogenetic methods and findings in human solid tumors 577

Marilu Nelson

12.1 Introduction	577
12.1.1 Historical review	577
12.1.2 Tumor classification	578
12.2 Processing tumor specimens	579
12.2.1 Culture of tumor cells	579
12.2.2 Specimen requirements	579
12.2.3 Specimen transport	580
12.2.4 Specimen receipt	580
12.2.5 Culture media and supplementation	581
12.2.6 Culture vessels	581
12.2.7 Tissue dissociation	581
12.2.8 Cell dilution and culture initiation	583
12.2.9 Culture maintenance and duration	583
12.2.10 Mitotic arrest	584
12.2.11 Cell synchrony	585
12.2.12 Determination of harvest time	585
12.2.13 Hypotonic treatment	585
12.2.14 Fixation	586
12.2.15 Slide preparation and staining	586
12.2.16 Chromosome analysis	587
12.3 Recurrent cytogenetic abnormalities	592
12.3.1 Benign adipose tumors	592
12.3.2 Malignant adipocytic tumors	594
12.3.3 Skeletal muscle tumors	596
12.3.4 Tumors of uncertain differentiation	597
12.3.5 Bone tumors	599
12.3.6 Tumors of the nervous system	599
12.3.7 Tumors of the lung	603
12.3.8 Tumors of the liver	604
12.3.9 Tumors of the thymus	604
12.3.10 Tumors of the salivary glands	604
12.3.11 Tumors of the prostate	605
12.3.12 Tumors of the kidney	605
12.3.13 Tumors involving germ cells of testicular or ovarian origin	607
12.3.14 Tumors of the pleura	607
12.4 Molecular genetic and cytogenetic techniques	608
12.4.1 FISH applications	608
12.4.2 RT-PCR	611
12.4.3 Chromosome microarray analysis and multicolor karyotyping	611
12.5 Conclusion	612
Glossary	612
References	613
Contributed protocol section	631
Protocol 12.1 Solid tumor cell culture and harvest	631
Protocol 12.2 Solid tumor cell culture and harvest	637
Protocol 12.3 Solid tumor culture	643
Protocol 12.4 Solid tumor harvest: monolayer and flask methods	644
Protocol 12.5 Solid tumor culturing and harvesting	646

13 Chromosome instability syndromes**653***Yasmine Akkari*

13.1	Introduction	653
13.1.1	Cytogenetics versus molecular diagnosis	654
13.2	Fanconi anemia	656
13.2.1	Cytogenetic diagnosis of Fanconi anemia	656
13.2.2	Somatic mosaicism in Fanconi anemia	658
13.3	Bloom syndrome	658
13.4	Ataxia-telangiectasia	658
13.5	Nijmegen breakage syndrome	659
13.6	Immunodeficiency, centromeric instability, and facial anomalies syndrome	660
13.7	Roberts syndrome	661
13.8	Werner syndrome	661
13.9	Rothmund-Thomson syndrome	662
13.10	Proficiency testing	662
	Glossary	662
	References	667
	Contributed protocol section	671
	Protocol 13.1 Fanconi anemia chromosome breakage procedure for whole blood	671
	Protocol 13.2 Supplemental procedure; Ficoll separation of whole blood	675
	Protocol 13.3 Fanconi anemia fibroblast set up, culture, subculture, and harvest procedure	676
	Protocol 13.4 Fanconi anemia chromosome breakage analysis policy	681
	Protocol 13.5 Table for breakage studies result interpretation	682
	Protocol 13.6 Fanconi anemia	684

14 Microscopy and imaging**687***Margaret J. Barch and Helen J. Lawce*

14.1	The standard microscope	687
14.1.1	The light path	688
14.1.2	Magnification, numerical aperture, and resolution	689
14.1.3	Lenses	690
14.1.4	Condensers	692
14.1.5	Eyepieces (or oculars)	693
14.1.6	Homogenous system	694
14.1.7	Mechanical stages	694
14.1.8	Practical microscopy	694
14.1.9	Cleaning the microscope	694
14.2	Brightfield microscopy	695
14.2.1	Köhler illumination	695
14.2.2	Filters	695
14.2.3	Immersion oil	696
14.2.4	Coverglass	696
14.2.5	Slides	696
14.2.6	Eyepiece adjustment	697
14.3	Fluorescence microscopy	697
14.3.1	Light sources for fluorescence	697
14.3.2	Filters for fluorescence	699
14.3.3	Practical advice for fluorescence	699
14.4	Specialized microscopy	699
14.4.1	Phase contrast microscopy	699
14.4.2	Inverted microscope	701
14.5	Capturing the microscopic image	701
14.5.1	Brightfield photography	701
14.5.2	Digital imaging	702

14.5.3	Printer	703
14.5.4	Modern advances in microscopy tools	703
	References	703
15	Computer imaging	705
	<i>Christine E. Haessig</i>	
15.1	Introduction	705
15.2	Techniques to improve karyogram image quality	705
15.3	Metaphase preparation	706
15.3.1	Use of phase contrast	706
15.3.2	Chromosome length and staining	706
15.3.3	Band resolution	706
15.4	Microscopy	706
15.4.1	Köhler illumination	706
15.4.2	Magnification	707
15.4.3	Focus	707
15.5	Image capture	707
15.5.1	Computer gray levels	707
15.5.2	Gray scale	708
15.5.3	Indicator chromosomes	710
15.6	Enhancement	710
15.6.1	Sharpening	710
15.6.2	Contrast	710
15.7	Advanced contrast	710
15.7.1	Pink/blue sliders	711
15.7.2	Brighten/darken contrast slider	711
15.7.3	Cutoff % sliders	711
15.8	Macro programming	712
15.9	FISH imaging	713
15.9.1	Microscope setup	713
15.9.2	Thresholding	714
15.9.3	Probe enhancement tips	714
15.10	Printing	715
15.11	Quality control	715
15.12	Archiving	715
	Acknowledgments	715
	References	715
16	Fluorescence in situ hybridization (FISH)	717
	<i>Helen J. Lawce and Jeffrey S. Sanford</i>	
16.1	Introduction	717
16.1.1	Molecular mechanisms of FISH	717
16.1.2	Historical development of FISH	717
16.1.3	FISH of today	719
16.2	Clinical applications of FISH probes	722
16.2.1	In vitro diagnostics versus analyte-specific reagents	722
16.2.2	Probe designs	722
16.3	Deletion/duplication probes for constitutional abnormalities	730
16.3.1	Subtelomeric-specific probes	732
16.3.2	All-human telomere probes	733
16.4	Hematology/oncology and solid tumor probes	734
16.4.1	Cancer-related deletion probes	734
16.4.2	Cancer-related enumeration probes	735

16.4.3	Cancer-related locus-specific probes	735
16.4.4	Cancer-related paint probes	735
16.4.5	Cancer probe panels	736
16.5	Sources and characteristics of probes available to the clinical cytogenetics laboratory	736
16.5.1	Probe size	737
16.5.2	Probe concentration	738
16.5.3	Probe terminology/nomenclature	738
16.5.4	Probe storage	738
16.6	Special uses of probes	738
16.6.1	Mixing probes of different brands or kinds	738
16.6.2	Off-label use of probes	739
16.7	Important FISH probe adjuvants	739
16.7.1	Cot-1® blocking DNA	739
16.7.2	Probe buffers	740
16.8	Principles of FISH	741
16.8.1	Principles of fluorescence	741
16.8.2	Stringency in FISH assays	741
16.8.3	Fluorescent background in the FISH assay	743
16.9	FISH methods – an overview	744
16.9.1	Specimen	745
16.9.2	Harvest/cell preparation	747
16.9.3	Slide preparation	748
16.9.4	Pretreatments for FISH slides	749
16.9.5	Denaturation of probes and target	751
16.9.6	Coverslips, sealants, and alternatives	752
16.9.7	Renaturation (reannealing) times and temperatures	753
16.9.8	Post-hybridization wash	753
16.9.9	Detection	753
16.9.10	Slide mounting and counterstains	754
16.9.11	Storage of hybridized slides	754
16.9.12	Safety precautions	757
16.10	FISH analysis and reporting	757
16.10.1	Microscopy	757
16.10.2	Scoring cells	758
16.10.3	Capturing and working with FISH signal images	764
16.10.4	Reporting results	765
16.10.5	FISH and mosaicism	765
16.11	FISH probe testing and validation	765
16.11.1	Sensitivity, specificity, and efficiency	765
16.11.2	Establishing cutoffs	766
16.11.3	FISH controls	768
16.12	FISH for special investigation	768
16.12.1	Sequential staining methods combined with FISH	768
16.12.2	Rx-FISH	769
16.12.3	Fiber FISH	770
16.13	Preimplantation genetic FISH	771
16.13.1	Obtaining samples for PGD FISH	771
16.13.2	PGD technical issues	773
16.13.3	Designing translocation probe sets for balanced carrier patients	773
16.13.4	Preimplantation FISH abnormalities	773
16.13.5	Technical issues for preimplantation FISH	774
16.13.6	PGD FISH methods	774
16.13.7	Scoring PGD samples	775
16.13.8	Sperm FISH	775
16.13.9	PRINS	775

16.14 Other applications	776
16.14.1 Array CGH confirmation FISH	776
16.14.2 FISH for bladder cancer	776
16.15 Variants in FISH signal patterns	777
16.15.1 Alpha satellite DNA probes	777
16.15.2 Subtelomere-specific probes	777
16.15.3 Locus-specific probes	777
16.16 Conclusion	777
Acknowledgments	778
Glossary	778
References	780
Contributed protocols	790
Protocol 16.1 FISH (fluorescence in situ hybridization) methods	790
Protocol 16.2 LSI, CEP, and paint probe protocol	796
Protocol 16.3 FISH protocol for multiprobe® FISH panels	799
Protocol 16.4 Slide pretreatment with pepsin for FISH	800
Protocol 16.5 Interphase FISH for amniotic fluid specimen aneuploidy	801
Protocol 16.6 FISH on direct preparations from abortus tissue	803
Protocol 16.7 FISH on cultured non-mitotic abortus tissue	804
Protocol 16.8 FISH on smears	806
Protocol 16.9 FISH on very small samples	808
Protocol 16.10 Paraffin-embedded tissue FISH method	810
Protocol 16.11 VP2000 automated slide processor method for FFPE FISH	811
Protocol 16.12 Plasma cell targeted FISH	814
Protocol 16.13 Plasma cell separation for interphase FISH using easy SEP magnet method	815
Protocol 16.14 Preimplantation genetic testing (PGD) for aneuploidy	818
Protocol 16.15 Preimplantation genetic testing (PGD) FISH for translocations	821
Protocol 16.16 Post-FISH BrdU antibody detection	823
Protocol 16.17 Same-day HER2 IQ-FISH pharmDx™ for breast tissue	824
17 Multicolor FISH (SKY and M-FISH) and CGH	833
<i>Turid Knutsen</i>	
17.1 Introduction	833
17.1.1 Online databases	833
17.2 Multicolor FISH (SKY/M-FISH)	834
17.2.1 Introduction	834
17.2.2 Other multicolor FISH techniques	834
17.2.3 Theory	835
17.2.4 Applications of multicolor FISH	837
17.2.5 Methodology	840
17.3 Comparative genomic hybridization	849
17.3.1 Introduction	849
17.3.2 Theory	851
17.3.3 Advantages and limitations	851
17.3.4 Applications of CGH	851
17.3.5 Methodology	853
17.4 Conclusion	859
Acknowledgments	859
References	859
Contributed protocols section	864
Protocol 17.1 Spectral karyotyping (SKY)	864
Protocol 17.2 Spectral karyotyping (SKY)	877
Protocol 17.3 DNA spectral karyotyping	878

Protocol 17.4 Multicolor-FISH method (M-FISH) I	881
Protocol 17.5 Multicolor FISH (M-FISH) or 24-color FISH II	884
Protocol 17.6 Multicolor FISH (M-FISH) III	888
Protocol 17.7 Comparative genomic hybridization I	891
Protocol 17.8 Comparative genomic hybridization II	898
18 Genomic microarray technologies for the cytogenetics laboratory	903
<i>Bhavana J. Davé and Warren G. Sanger</i>	
18.1 Introduction	903
18.1.1 Principle and advances	903
18.1.2 Advantages	905
18.1.3 Methods	906
18.2 Applications	907
18.2.1 CMA for identification of congenital genetic defects (constitutional abnormalities)	907
18.2.2 CMA for characterization of acquired genetic changes	909
18.2.3 Use of CMA in prenatal diagnostics	911
18.2.4 CMA in determination of genomic variations and polymorphisms	911
18.2.5 Evolutionary characterization with CMA	912
18.2.6 Limitations	912
18.3 Genomic microarray in a cytogenetics laboratory	913
18.3.1 General considerations	913
18.3.2 Specimens	913
18.3.3 Types of microarray used in the clinical laboratory	914
18.3.4 Microarray data analysis	914
18.3.5 Aspects specific to the validation of home-brew microarrays	914
18.3.6 Validation of FDA-approved commercial, IVD commercial, or home-brew microarrays	914
18.3.7 Confirmation of abnormal CMA results	915
18.3.8 Genomic polymorphisms and variations	915
18.3.9 Reporting CMA results	915
18.3.10 Examples	915
18.4 Conclusion	922
Acknowledgment	922
Authors' note	923
References	923
19 Mathematics for the cytogenetic technologist	937
<i>Patricia K. Dowling</i>	
19.1 General concepts	937
19.1.1 Scientific notation	937
19.1.2 Manipulating numbers written in scientific notation	939
19.1.3 Unit conversion	940
19.2 Solutions	942
19.2.1 Definitions	942
19.2.2 Moles and molarity	943
19.2.3 Preparing a molar solution	943
19.2.4 Making molar solutions using hydrated compounds	945
19.2.5 Making percent solutions	946
19.2.6 Stock solutions	947
19.2.7 Diluting molar solutions	947
19.2.8 Diluting a stock molar solution to a specific concentration	947
19.2.9 Using dilution ratios	949
19.2.10 Converting molarity to percent	951
19.2.11 Converting percent to molarity	951
19.2.12 Serial dilutions (application for dose-response experiments)	951

19.3 Statistical tools	956
19.3.1 Determining the normal cut-off for FISH validation	956
19.3.2 Other statistics of use in the cytogenetics laboratory	961
19.3.3 Choosing the right method to fit the situation	965
19.4 Using a hemacytometer	968
19.4.1 Determining cell count by using a hemacytometer	968
19.4.2 Determining cell viability using a hemacytometer	972
19.5 Quantification and purity determination of DNA using spectroscopy	973
Reference	974
Additional readings	974
20 Selected topics on safety, equipment maintenance, and compliance for the cytogenetics laboratory	975
<i>Helen Jenks and Janet Krueger</i>	
20.1 Introduction	975
20.2 Biological hazard safety	975
20.2.1 Safety program	975
20.2.2 Work practice controls	977
20.2.3 Personal protective equipment	977
20.2.4 Universal (or standard) precautions	977
20.2.5 Engineering controls	979
20.2.6 Housekeeping procedures	979
20.2.7 Biological hazard spills	979
20.3 Chemical safety	980
20.3.1 Know your chemicals	980
20.3.2 Proper chemical storage	983
20.3.3 Fume hoods	984
20.3.4 Working with chemicals	985
20.3.5 Chemical emergencies	985
20.4 Fire safety	986
20.4.1 Fire prevention unit	986
20.4.2 Fire drills	986
20.4.3 Fire extinguishers	986
20.5 Electrical safety	987
20.6 Disaster plan	988
20.7 Equipment operation, maintenance, and safety	988
20.7.1 Autoclaves	990
20.7.2 Compressed gas cylinders	990
20.7.3 Centrifuges	990
20.7.4 Thermometers	991
20.7.5 Refrigerators/freezers	991
20.7.6 Ovens	992
20.7.7 Water baths	992
20.7.8 Microscopes	992
20.7.9 Environmental control chamber	992
20.7.10 Biological safety cabinets	993
20.7.11 Pipettes	993
20.7.12 pH meter	994
20.7.13 Scales	994
20.7.14 Timers	994
20.7.15 Incubators	994
20.7.16 Fume hoods	995
20.7.17 Automated hybridization system	995
20.7.18 Robotic harvester	995
20.8 Ergonomics	996

20.9 Regulatory considerations	998
20.9.1 Incident reporting	998
20.9.2 Privacy act	998
20.9.3 Safety inspections/drills/training	999
20.9.4 Compliance	999
20.9.5 US regulatory and accreditation agencies	1000
Acknowledgments	1001
References	1001
Contributed protocols section	1003
Protocol 20.1 Autoclave sterilization, liquid nitrogen, pro-par	1003
Protocol 20.2 Dishwashing procedure	1003
Protocol 20.3 Eppendorf pipette calibration	1004
Protocol 20.4 NIST thermometer calibration	1006
Protocol 20.5 Thermometer calibration	1008
Protocol 20.6 Timer calibration	1008
21 A system approach to quality	1011
<i>Peggy J. Stupca and Sheryl A. Tran</i>	
21.1 Quality system	1011
21.1.1 What is the quality system?	1011
21.1.2 Organization	1012
21.1.3 Facilities and safety	1012
21.1.4 Personnel	1012
21.1.5 Purchasing and inventory	1012
21.1.6 Equipment	1012
21.1.7 Process management	1012
21.1.8 Documents and records	1012
21.1.9 Nonconforming event management	1012
21.1.10 Assessments	1012
21.1.11 Customer focus	1012
21.1.12 Information management	1013
21.1.13 Continual improvement	1013
21.2 Process management	1013
21.2.1 Validating new tests, changed tests, and new or moved equipment	1013
21.2.2 Validation plan	1013
21.2.3 Specimen number for validation	1014
21.2.4 Data analytical evaluation	1015
21.2.5 Reference range maintenance	1015
21.3 Documents and records	1015
21.3.1 Document creation and control	1016
21.3.2 Records	1018
21.4 Assessments	1018
21.4.1 Internal assessments	1019
21.4.2 External assessments	1021
21.5 Continual improvement	1022
21.6 Summary	1023
References	1023
Contributed protocols section	1025
Protocol 21.1 Quality control overview document	1025
Protocol 21.2 Monitoring specimen quality from off-hill sites	1030
22 Laboratory management	1031
<i>Mervat S. Ayad and Adam Sbeiti</i>	
22.1 Introduction	1031
22.2 Management concepts and functions	1032
22.2.1 Planning (goal setting)	1032
22.2.2 Organizing/staffing needs	1032

22.2.3 Directing (leading)	1032
22.2.4 Monitoring (controlling)	1032
22.3 Personnel management	1033
22.3.1 Staff level assessment	1033
22.3.2 Job descriptions	1033
22.3.3 Selecting your team	1033
22.3.4 Training	1034
22.3.5 Competency	1034
22.3.6 Performance evaluation and appraisals	1035
22.3.7 Staff motivation and retention	1035
22.3.8 Policy manual	1036
22.4 Quality management and control	1036
22.4.1 Technology assessment and implementation	1036
22.4.2 Financial management	1037
22.4.3 Cost per test	1038
22.4.4 Productivity and workload	1038
22.5 Budget development and monitoring	1039
22.5.1 Forecast	1039
22.5.2 Budgeting	1040
22.5.3 Capital expenditure	1041
22.5.4 Trends and measures	1042
22.6 Conclusion	1043
References	1043
Suggested reading	1043
23 Laboratory information system	1045
<i>Peining Li and Richard Van Rheeden</i>	
23.1 Historical perspective	1045
23.2 General description of LIS	1045
23.2.1 LIS concept	1045
23.2.2 Software architecture and hardware considerations	1046
23.2.3 Validation and implementation	1047
23.2.4 Compliance and security	1048
23.3 LIS in cytogenetics laboratories	1048
23.3.1 The CytoGen system from Washington University in St. Louis	1048
23.3.2 Examples of other cytogenetic LIS systems	1051
23.4 Trends for the future LIS	1051
Acknowledgments	1052
References	1052
24 Animal cytogenetics	1055
<i>Marlys L. Houck, Teri L. Lear and Suellen J. Charter</i>	
24.1 Introduction	1055
24.2 Domestic animal fertility	1056
24.2.1 Cattle	1056
24.2.2 Horses	1056
24.3 Captive management	1057
24.3.1 Species integrity	1057
24.3.2 Chromosome abnormalities	1057
24.3.3 Studbooks	1058
24.4 Wildlife conservation	1059
24.5 General sample collection considerations	1060
24.5.1 Regulations	1060
24.5.2 Record keeping	1062

24.6	Fibroblast cell culture	1062
24.6.1	Bioresource banking	1062
24.6.2	Fibroblast sample sources	1062
24.6.3	Fibroblast culture conditions	1063
24.7	Peripheral blood culture	1063
24.8	Chromosome analysis	1064
24.8.1	Conventional staining	1064
24.8.2	Banding	1065
24.8.3	Digital imaging	1066
24.8.4	Karyotyping	1066
24.8.5	Karyotype standards and precedents	1068
24.9	Molecular and comparative cytogenetics	1070
24.9.1	Zoo-FISH	1070
24.9.2	Reciprocal chromosome painting	1070
24.9.3	BAC maps	1071
24.9.4	Future directions	1071
	Acknowledgments	1071
	Glossary	1072
	References	1072
	Contributed protocol section	1078
Protocol 24.1	Blood feather collection	1078
Protocol 24.2	Avian lymphocyte culture (for large birds)	1078
Protocol 24.3	Lymphocyte culture using whole blood	1084
Protocol 24.4	Lymphocyte culture using autologous plasma/buffy coat (AP/BC)	1085
Protocol 24.5	Horse lymphocyte culture method	1087
Protocol 24.6	Rhino blood culture	1089
Protocol 24.7	Organ tissue collection protocol from carcass	1090
Protocol 24.8	Skin biopsy procedure	1090
Protocol 24.9	Placenta biopsy procedure	1091
Protocol 24.10	Freezing of fibroblast cell cultures	1092
Protocol 24.11	Freezing tissue biopsy samples for later initiation of cell culture (tissue piecing)	1094
Protocol 24.12	Preparation of primary cultures from feather pulp	1095
Protocol 24.13	Preparation of primary cultures from solid tissue (explants)	1096
Protocol 24.14	Preparation of primary cultures using enzyme digestion	1097
Protocol 24.15	Harvesting of fibroblast cell cultures	1098
Protocol 24.16	Preparation of competitor DNA for FISH hybridization	1099
Protocol 24.17	In situ hybridization of BAC clones labeled with spectrum fluorochromes: probe and slide preparation	1100
Protocol 24.18	Labeling DNA with spectrum fluorochromes	1102
25	Online genetic resources and references	1103
	<i>Wahab A. Khan</i>	
25.1	Introduction	1103
25.2	Resource information	1103
25.2.1	Databases, laboratory tools and educational tutorials	1103
25.2.2	Bioinformatic resources	1105
25.2.3	Links to cytogenetics and genomics support groups	1106
25.2.4	Prominent peer-reviewed journals pertaining to genetics	1107
25.2.5	Cytogenetics and medical genetics textbooks	1107
25.2.6	Vendor products/equipment and lab support	1108
25.2.7	Credentialing and guidelines	1110
25.2.8	Genetics training programs and courses	1111
25.2.9	Professional organizations	1112
25.2.10	Job search	1112
	Index	1113